Despite significant progress in medical imaging technologies, the need for more specific information on a molecular level for the detection of early metabolic and genetic changes in vivo has not been fully addressed. Developing novel molecular imaging technologies and improving the existing ones by designing better probes and increasing specificity and bioavailability is key for early detection of diseases on a molecular basis and the development of targeted therapeutics. This conference will examine the development of specific and efficient intracellular targeting and imaging systems which provide high resolution as well as high sensitivity.

Scientific Advisory Board
William Dow, Ph.D., Alerion Biomedical, Inc.
Harvey R. Herschman, Ph.D., University of California, Los Angeles 
Derek Maclean, Ph.D., KAI Pharmaceuticals
Anthony Purchio, Ph.D., CSO, Xenogen, Inc. 

Sessions Speakers
Technology Innovations
Timothy J. Pelura, Ph.D., Kereos, Inc.
Shuming Nie, Ph.D., Georgia Institute of Technology and Emory University School of Medicine
Douglas A. Bakan, Ph.D., Alerion Biomedical, Inc.
Michael Thornton, GE Healthcare
Derek Maclean, Ph.D., KAI Pharmaceuticals

Pre-Clinical Imaging
Aladar A. Szalay, Ph.D., University of Wurzburg, and Genelux Corporation
Jan E. Schnitzer, M.D., Sidney Kimmel Cancer Center
Amos Baruch, Ph.D., Celera Genomics 
Nikolaus S. Trede, M.D., Ph.D., Harvard Medical School
Harvey R. Herschman, Ph.D., University of California, Los Angeles 
Anthony Purchio, Ph.D., CSO, Xenogen, Inc. 

Clinical Applications
Annick D. Van den Abbeele, M.D., Dana-Farber Cancer Institute and Harvard Medical School
Johannes Czernin, M.D., University of California, Los Angeles